RXRX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own RXRX shares is 367, representing 68.89% of the company's common stock.

GOLDMAN SACHS GROUP INC, in the last quarter, reduced its stake in RXRX by -24.73% restricting it's holding to 897.02 thousand shares of worth nearly $8.94M. RAFFERTY ASSET MANAGEMENT, LLC also lessened -18.34% of the RXRX shares from its portfolio, reducing its holding to 890.24 thousand shares of worth $8.88M. UBS GROUP AG also shunned RXRX shares holding by -2.82% last quarter which brought its holding to 672.43 thousand shares worth $6.70M.

As per its latest 13F filing, CITADEL ADVISORS LLC increased its stake in RXRX by 832.68% in the last quarter. The institutional holder raised its holding to 340.37 thousand shares having worth more than $3.39M. TWO SIGMA INVESTMENTS, LP also added 68.31% more shares of RXRX to its portfolio, raising its holding to 896.48 thousand shares of worth $8.94M. VESTMARK ADVISORY SOLUTIONS, INC. also increased its RXRX shares holding by 90.58% which brought its holding to 900.02 thousand shares worth $8.97M.

The insider with the most stakes in RXRX is Borgeson Blake , director at the company. Additionally, RXRX stock is highly held by Chief Financial Officer Secora Michael and Chief Executive Officer Gibson Christopher among others.

Company executives, directors, and other insiders own 3.5% percent of Recursion Pharmaceuticals, Inc.'s stock. Within the last six months, there have been 28 transaction(s) in which RXRX insiders have sold stock, totaling 418.13K shares. Insiders that have sold shares include GIBSON CHRISTOPHER, SECORA MICHAEL, and BORGESON BLAKE.

There have been 0 transaction(s) during the past 6-months in which Recursion Pharmaceuticals, Inc. insiders have bought stock, totalling 0 shares

Around 70.12M Recursion Pharmaceuticals, Inc. shares are held by insiders, which represents about 3.5% of RXRX stock.

RXRX director, Borgeson Blake holds the largest portfolio of the company's shares. RXRX shares owned by Borgeson total nearly 7.07 million.

CITADEL ADVISORS LLC is the largest institutional owner in RXRX which holds 340.37 thousand shares worth $3.39M or 0.15% of the total RXRX shares outstanding followed by COMPREHENSIVE FINANCIAL MANAGEMENT LLC with ownership of 941.9 thousand shares representing 0.4% of the RXRX ownership. GOLDMAN SACHS GROUP INC is the third largest stakeholder with 897.02 thousand shares or 0.38% of the ownership worth more than $8.94M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the RXRX is concerned, it is a stock which is optionable.

Number of RXRX shares short is 67.86M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 383.72M shares of RXRX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, RXRX has 252.42M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for RXRX is 4.15.